These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24163149)

  • 1. Effect of rosuvastatin on OX40L and PPAR-γ expression in human umbilical vein endothelial cells and atherosclerotic cerebral infarction patients.
    Zhang JY; Liu B; Wang YN; Zhang WN; Wang FJ
    J Mol Neurosci; 2014 Feb; 52(2):261-8. PubMed ID: 24163149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rosuvastatin on fibrinolytic system of human umbilical vein endothelial cells in vitro.
    He F; Zhao J; Guo R; Liang Y
    Am J Med Sci; 2014 Oct; 348(4):319-23. PubMed ID: 24694789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin reduces OX40 and OX40 ligand expression in human peripheral blood mononuclear cells and in patients with atherosclerotic cerebral infarction.
    Liu B; Yu G; Yang Z; Sun L; Song R; Liu F; Xin Y; Zhang L
    J Int Med Res; 2009; 37(3):601-10. PubMed ID: 19589242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosuvastatin increases vascular endothelial PPARgamma expression and corrects blood pressure variability in obese dyslipidaemic mice.
    Desjardins F; Sekkali B; Verreth W; Pelat M; De Keyzer D; Mertens A; Smith G; Herregods MC; Holvoet P; Balligand JL
    Eur Heart J; 2008 Jan; 29(1):128-37. PubMed ID: 18063594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosuvastatin inhibits MMP-2 expression and limits the progression of atherosclerosis in LDLR-deficient mice.
    Guo H; Shi Y; Liu L; Sun A; Xu F; Chi J
    Arch Med Res; 2009 Jul; 40(5):345-51. PubMed ID: 19766896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-γ activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A₂.
    Rizos CV; Liberopoulos EN; Tellis CC; Florentin M; Elisaf MS; Tselepis AD
    Metab Syndr Relat Disord; 2011 Jun; 9(3):217-23. PubMed ID: 21352079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of lipid-lowering therapy with rosuvastatin on atherosclerotic burden in patients with chronic kidney disease.
    Sawara Y; Takei T; Uchida K; Ogawa T; Yoshida T; Tsuchiya K; Nitta K
    Intern Med; 2008; 47(17):1505-10. PubMed ID: 18758125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of combined treatment with rosuvastatin and protein kinase Cβ2 inhibitor on angiogenesis following myocardial infarction in diabetic rats.
    Huang D; Wang FB; Guo M; Li S; Yan ML; Yu T; Wei M; Li JB
    Int J Mol Med; 2015 Mar; 35(3):829-38. PubMed ID: 25524396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved cardiac performance by rosuvastatin is associated with attenuations in both myocardial tumor necrosis factor-alpha and p38 MAP kinase activity in rats after myocardial infarction.
    Xu Y; Tang T; Ding Y; Yao R; Xie J; Liao M; Xiao H; Chen Y; Yu X; Fu M; Liao Y; Zhao G; Cheng X
    Am J Med Sci; 2010 Aug; 340(2):121-7. PubMed ID: 20588182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rosuvastatin restores superoxide dismutase expression and inhibits accumulation of oxidized LDL in the aortic arch of obese dyslipidemic mice.
    Verreth W; De Keyzer D; Davey PC; Geeraert B; Mertens A; Herregods MC; Smith G; Desjardins F; Balligand JL; Holvoet P
    Br J Pharmacol; 2007 Jun; 151(3):347-55. PubMed ID: 17384667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study.
    Rizos CV; Milionis HJ; Kostapanos MS; Florentin M; Kostara CE; Elisaf MS; Liberopoulos EN
    Clin Ther; 2010 Mar; 32(3):492-505. PubMed ID: 20399986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.
    Kathuria S; Mahadevan N; Balakumar P
    Mol Cell Biochem; 2013 Feb; 374(1-2):61-72. PubMed ID: 23149826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ox-LDL increases OX40L in endothelial cells through a LOX-1-dependent mechanism.
    Dong Q; Xiang R; Zhang DY; Qin S
    Braz J Med Biol Res; 2013 Sep; 46(9):765-70. PubMed ID: 24068192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacological and clinical profile of rosuvastatin calcium (Crestor)].
    Ohfuji K; Yano S; Yamaguchi M; Smith G; Hirata M; Shimada H; Izuishi K; Shinagawa J; Matsunaga K
    Nihon Yakurigaku Zasshi; 2005 Sep; 126(3):213-9. PubMed ID: 16272766
    [No Abstract]   [Full Text] [Related]  

  • 16. Rosuvastatin attenuates atherosclerosis in rats via activation of scavenger receptor class B type I.
    Li Y; Wang Q; Zhou J; Xu Q; Chu X; Sun T; Liu X; Cai S
    Eur J Pharmacol; 2014 Jan; 723():23-8. PubMed ID: 24333476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin promotes the differentiation of peripheral blood monocytes into M2 macrophages in patients with atherosclerosis by activating PPAR-γ.
    Zhang T; Shao B; Liu GA
    Eur Rev Med Pharmacol Sci; 2017 Oct; 21(19):4464-4471. PubMed ID: 29077145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice.
    Laufs U; Gertz K; Dirnagl U; Böhm M; Nickenig G; Endres M
    Brain Res; 2002 Jun; 942(1-2):23-30. PubMed ID: 12031849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rosuvastatin improves plaque morphology in cerebral embolism patients with normal low-density lipoprotein and severe aortic arch plaque.
    Kaneko K; Saito H; Takahashi T; Kiribayashi N; Omi K; Sasaki T; Niizeki T; Sugawara S; Akasaka M; Kubota I
    J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1682-9. PubMed ID: 24739590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy analysis of the lipid-lowering and renoprotective effects of rosuvastatin in patients with chronic kidney disease.
    Abe M; Maruyama N; Yoshida Y; Ito M; Okada K; Soma M
    Endocr J; 2011; 58(8):663-74. PubMed ID: 21670545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.